European Regulatory Strategy ‘Should Prioritize Real World Evidence’
Innovative Clinical Trials Should Be Priority Too, Says EFPIA.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.
You may also be interested in...
A two-day workshop saw EU policymakers and regulators meet with dozens of representatives from the pharmaceutical, health and medtech industries to discuss the future of regulating AI in medicine and its uses in the medicinal product lifecycle.
Agreement on a new, more streamlined fee structure for the European regulator could be reached by the end of this year.
Regulators have produced yet another strategy outlining the challenges and next steps for the European drug regulatory network as the network prepares for a future characterized by rapid developments in science and technology, medicines access issues, supply chain weaknesses and emerging health threats.